U.S. markets closed
  • S&P Futures

    3,397.75
    +4.25 (+0.13%)
     
  • Dow Futures

    27,626.00
    +45.00 (+0.16%)
     
  • Nasdaq Futures

    11,504.50
    +12.25 (+0.11%)
     
  • Russell 2000 Futures

    1,604.90
    +2.80 (+0.17%)
     
  • Crude Oil

    38.71
    +0.15 (+0.39%)
     
  • Gold

    1,910.50
    +4.80 (+0.25%)
     
  • Silver

    24.60
    +0.18 (+0.76%)
     
  • EUR/USD

    1.1823
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    0.8010
    -0.0400 (-4.76%)
     
  • Vix

    32.46
    +4.91 (+17.82%)
     
  • GBP/USD

    1.3034
    +0.0013 (+0.10%)
     
  • USD/JPY

    104.7090
    -0.1260 (-0.12%)
     
  • BTC-USD

    13,079.33
    -29.46 (-0.22%)
     
  • CMC Crypto 200

    260.58
    -2.83 (-1.08%)
     
  • FTSE 100

    5,792.01
    -68.27 (-1.16%)
     
  • Nikkei 225

    23,428.70
    -65.64 (-0.28%)
     

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif.--(BUSINESS WIRE)--

Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

  • Jefferies 2019 London Healthcare Conference
    Date: Wednesday, November 20, 2019
    Presentation Time: 3:20 p.m. GMT
    Location: London

  • Piper Jaffray 31st Annual Healthcare Conference
    Date: Tuesday, December 3, 2019
    Presentation Time: 8:00 a.m. EST
    Location: New York

Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005714/en/